Dr. Henry E Wiley, M.D.

Claim this profile
Studies Macular Degeneration
Studies Age-Related Macular Degeneration
1 reported clinical trial
3 drugs studied

Clinical Trials Henry E Wiley, M.D. is currently running

Image of trial facility.

Stem Cell Transplant

for Age-Related Macular Degeneration

Background: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots. Researchers want to learn if replacing older eye cells with younger ones can help treat this disease. Objective: To test the safety of putting cells inside the eye as a possible future treatment for dry age-related macular degeneration. Eligibility: People ages 55 and older who have geographic atrophy with loss of vision. People who have had "wet" macular degeneration in study eye are NOT eligible. Design: Participants will be screened with: * Medical history * Physical exam * Blood and urine tests * Eye exam * Eye photos * Fluorescein angiography. An intravenous (IV) line is placed in an arm vein. A dye is injected. A camera takes pictures of the dye as it flows through the eyes' blood vessels. * Electroretinography. An electrode is taped to participants' forehead. They sit in the dark. After 30 minutes, numbing eye drops and contact lenses are placed in their eyes. They watch flashing lights. * Tuberculosis test * Chest X-ray * Electrocardiography. Sticky pads are placed on participants' chest to record the heart's electrical activity. Participants will have at least 14 study visits over 5 and a half years. They will repeat screening tests. Participants will have retinal pigment epithelium (RPE) transplantation surgery in one eye. For this, cells from participants' blood are turned into RPE cells. These cells are placed in their eye through a cut in their retina. They will get dilating eye drops, an IV line, and anesthesia that may make them sleep. A gas bubble will be put in their eye to help it heal. Participants will receive immunosuppressive medications to avoid transplant rejection. Participants will be contacted yearly for up to 15 years.
Recruiting1 award Phase 1 & 2

More about Henry E Wiley, M.D.

Clinical Trial Related4 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Henry E Wiley, M.D. has experience with
  • Atuologous IPSC-derived RPE On PGLA
  • IPSC-derived RPE/PGLA Transplantation
  • IPSC-derived RPE/PLGA Transplantation

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Henry E Wiley, M.D. specialize in?
Henry E Wiley, M.D. focuses on Macular Degeneration and Age-Related Macular Degeneration. In particular, much of their work with Macular Degeneration has involved treating patients, or patients who are undergoing treatment.
Is Henry E Wiley, M.D. currently recruiting for clinical trials?
Yes, Henry E Wiley, M.D. is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Henry E Wiley, M.D. has studied deeply?
Yes, Henry E Wiley, M.D. has studied treatments such as Atuologous iPSC-derived RPE on PGLA, iPSC-derived RPE/PGLA transplantation, iPSC-derived RPE/PLGA transplantation.
What is the best way to schedule an appointment with Henry E Wiley, M.D.?
Apply for one of the trials that Henry E Wiley, M.D. is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.